Top Pharma News - IgeaHub

Top Pharma News of the Week

Repatha® (Evolocumab) Phase 3 Cognitive Function Study Results Published In The New England Journal Of Medicine August 16, 2017 Amgen has announced that the New England Journal of Medicine (NEJM) published results from the Repatha® (evolocumab) cognitive function trial (EBBINGHAUS), which was conducted in a subset of patients enrolled in the randomized, placebo-controlled Repatha cardiovascular outcomes study (FOURIER). The … Continue reading Top Pharma News of the Week

Top 10 Oncology Pharmaceutical Companies 2017

Top 10 Oncology Pharmaceutical Companies 2017

The market for oncology medication is booming, aiding the overall pharmaceutical industry growth. The oncology drug market is estimated to be almost USD 94 billion. Most of the top pharmaceutical players are either currently manufacturing oncology drugs or have oncology medications in their R&D pipelines. An analysis of the top pharmaceutical companies was conducted to … Continue reading Top 10 Oncology Pharmaceutical Companies 2017

Top Pharma News - IgeaHub

Top Pharma News of the Week

Amgen Submits Supplemental Biologics License Application for Prolia® (denosumab) In Glucocorticoid-Induced Osteoporosis  July 31, 2017 Amgen has announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Prolia® (denosumab) for the treatment of patients with glucocorticoid-induced osteoporosis (GIOP). The sBLA is based on a Phase 3 study evaluating the … Continue reading Top Pharma News of the Week

Top Pharma News - IgeaHub

Top Pharma News | July – August 2017

Phase 3 Study Evaluating the Safety and Efficacy of Adjuvant Opdivo in Resected High-Risk Melanoma Patients Meets Primary Endpoint July 5, 2017 Bristol-Myers Squibb Company has announced that a Phase 3 study evaluating Opdivo 3 mg/kg versus Yervoy 10 mg/kg in patients with stage IIIb/c or stage IV melanoma who are at high risk of recurrence following complete surgical resection met its … Continue reading Top Pharma News | July – August 2017

Top Pharma News - IgeaHub

Top Pharma News of the Week

Amgen and Array BioPharma Announce Preclinical License And Collaboration Agreement In Inflammation July 18, 2017 Amgen and Array BioPharma have announced a collaboration agreement for the discovery and development of novel drugs for autoimmune disorders. The undisclosed target and lead inhibitors were discovered through Array's proprietary platform that leverages Array's expertise in chemistry and early lead development. EU … Continue reading Top Pharma News of the Week

Top Pharma News - IgeaHub

Top Pharma News | May – June 2017

AstraZeneca’s Imfinzi (durvalumab) receives US FDA accelerated approval for previously treated patients with advanced bladder cancer 01 May 2017 AstraZeneca and its global biologics research and development arm, MedImmune, have announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Imfinzi (durvalumab). Imfinzi is indicated for the treatment of patients with locally advanced or metastatic … Continue reading Top Pharma News | May – June 2017

Top Pharma News - IgeaHub

Top Pharma News | March – April 2017

Bristol-Myers Squibb Planning Collaboration with GRAIL on Blood-Based Cancer Screening March 1, 2017 Bristol-Myers Squibb Company plans for a research collaboration with GRAIL Inc., a life sciences company whose mission is to detect cancer early when it potentially can be cured. GRAIL aims to develop highly sensitive blood tests that detect cancer in its early … Continue reading Top Pharma News | March – April 2017

AstraZeneca Logo

AstraZeneca Rivals Tesaro Using PARP Inhibitor with Strong Ovarian Cancer Study Results

Mar 14, 2017 The PARP inhibitor of AstraZeneca, Lynparza, delay the recurrence of ovarian cancer by more than two years compared to a placebo, according to results from a phase III study presented recently. The strong benefits observed with Lynparza as ovarian cancer maintenance therapy exceeded investor expectations and bolsters AstraZeneca against a competing PARP inhibitor from Tesaro. … Continue reading AstraZeneca Rivals Tesaro Using PARP Inhibitor with Strong Ovarian Cancer Study Results

Top 10 Pharmaceutical Companies 2017

Top 10 Pharmaceutical Companies 2017

The global pharmaceutical market was estimated in USD 1.1 trillion in 2016. The global market is highly mature and consolidated. The top-10 pharmaceutical companies in this market had share of around 40% in 2016 and approximately 50% considering the top-15. A comparative analysis of the top-15 organizations was used to develop a ranking for these … Continue reading Top 10 Pharmaceutical Companies 2017

AstraZeneca steps up with a $645M deal to partner with Sanofi on a late-stage RSV antibody

March 3, 2017 AstraZeneca has decided to partner with Sanofi on an experimental antibody for RSV. The French pharma giant is paying €120 million upfront and up to €495 million more in development and sales milestones to buy into the program. Now, the two Big Pharmas will split R&D costs for MEDI8897, with AstraZeneca in charge of … Continue reading AstraZeneca steps up with a $645M deal to partner with Sanofi on a late-stage RSV antibody